SIAG
VRTX icon

Safeguard Investment Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Safeguard Investment Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5
Closed -$1K – 711
2020
Q4 		$1K Buy
+5
New +$1.15K ﹤0.01% 694

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Safeguard Investment Advisory Group's VRTX Position: Q1 2021 in Review

Safeguard Investment Advisory Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2021, closing a stake of 5 shares — an estimated $1K sold.

Safeguard Investment Advisory Group first reported a position in VRTX in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 1,000 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

  • Safeguard Investment Advisory Group reported no remaining Vertex Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Safeguard Investment Advisory Group sold 5 Vertex Pharmaceuticals shares in Q1 2021, an estimated $1K.
  • Safeguard Investment Advisory Group first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Safeguard Investment Advisory Group's Vertex Pharmaceuticals position peaked at $1K in Q4 2020.
  • 1,000 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Safeguard Investment Advisory Group's 13F filing for Q1 2021, filed 10 May 2021.